Key result
A study assessed the length of initial hospitalisation in patients with symptomatic DVT or PE treated with rivaroxaban using records from the EINSTEIN trials.
Why the study?
Does oral rivaroxaban affect the length of initial hospitalisation in patients presenting with symptomatic DVT or PE?
Does oral rivaroxaban affect the length of initial hospitalisation in patients presenting with symptomatic DVT or PE?
This news snippet highlights a study assessing the length of initial hospitalisation for DVT and PE patients treated with rivaroxaban in the EINSTEIN trials.
Supports early discharge strategies for venous thromboembolism; extends the known efficacy of.
The phase III EINSTEIN deep vein thrombosis (DVT) and EINSTEIN pulmonary embolism (PE) trials demonstrated the potential of oral rivaroxaban (Xarelto, Bayer) -15 mg twice daily for 21 days, followed by 20 mg once daily -for the treatment of venous thromboembolism (VTE), a term that embraces DVT and PE. A subsequent study by van Bellen et al., [1] published in Current Medical Research and Opinion in 2014, was undertaken to assess the length of initial hospitalisation in patients presenting with either symptomatic DVT or PE using hospitalisation records from these trials.
No takes yet. Share an insight, caveat, or question.
Gertrude Fani (2017) studied Venous thromboembolism (DVT and PE). Oral rivaroxaban was evaluated on Length of initial hospitalisation. A study assessed the length of initial hospitalisation in patients with symptomatic DVT or PE treated with rivaroxaban using records from the EINSTEIN trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: